The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
These findings follow positive Phase 3 results presented earlier this year
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Subscribe To Our Newsletter & Stay Updated
